Identifying gaps in dermatological research and CSG reviews

On this page, we use several means to identify gaps in the evidence for ‘what works’ to improve the treatment of skin diseases in order to prioritise Cochrane Skin Group reviews.

As part of the SPRUSD programme grant carried out at the Centre of Evidence Based Dermatology two ‘Priority Setting Partnerships’ (PSP) in eczema and vitiligo were undertaken in collaboration with The James Lind Alliance. These exercises identified ‘uncertainties’ which are added to the Database of Uncertainties about the Effects of Treatments (DUETs).

The CSG has compared the results of the PSPs with our current portfolio of review titles

Uncertainties and gaps identified by the Eczema PSP
Uncertainties and gaps identified by the Vitiligo PSP

Other PSPs

Uncertainties and gaps identified by the Epidermolysis bullosa PSP
Uncertainties and gaps identified by the Hidradenitis suppurativa PSP
Uncertainties and gaps identified by the Acne PSP

Uncertainties and gaps identified by the Cellulitis PSP

Uncertainties and gaps identified by the Hair Loss PSP

Skin Cancer

We have mapped our current Cochrane Skin Group reviews on interventions for, and prevention of skin cancers. Our NIHR programme grant will concentrate on producing systematic reviews on diagnosis of skin cancers.

The Global Burden of Disease Project with the WHO has identified 13 skin conditions  within the scope of the Cochrane Skin Group that will help to guide our efforts. In the order in which they have an effect on DALYs (disability adjusted life years): dermatitis, acne, bacterial and viral skin diseases, urticaria, fungal skin diseases, pruritus, alopecia areata, cellulitis, melanoma, psoriasis, non-melanoma skin cancer and leprosy. 

The International League of Dermatology Societies (ILDS) have launched an initiative to address the challenge of achieving global skin health and have identified 9 criteria which should guide progress with NMSC, acne and psoriasis.